Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...

Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.

When Martijn Hoogerwerf first evaluated the Philippines’ sustainable finance market several years ago, the head of ING’s Sustainable Solutions Group for Asia Pacific found plenty of talk, little ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

Ahead is a different take on Phase 1 of the MCU. It moves quicker and brings in more characters early on to keep things fresh ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

As part of the deal, Sanofi is acquiring Blueprint’s rare immunology disease medication Ayvakit/Ayvakat, which has been approved in the U.S. and the EU for advanced and indolent systemic ...

Armor trims are smithing templates that apply various decorative designs to any armor part in Minecraft. These items were released with the 1.20 Trails and Tales update.

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

NEW YORK — It was always going to be on defense. For the New York Knicks to stave off elimination, to get back in this Eastern Conference finals, they needed to somehow curb the Indiana Pacers ...